Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
421 people get PRAN articles and Market Currents by email alert.
Get email alerts on PRAN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
5 Stocks That Finished in the Red on ThursdayAlex Shadunsky • Fri, Jul 15, 2011 -
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
5 Stocks That Finished in the Red on ThursdayAlex Shadunsky • Fri, Jul 15, 2011
-
-
-
-
-
-
There are no Transcripts on PRAN.
-
at MarketWatch.com (Sep 19, 2011)
-
at MarketWatch.com (Apr 20, 2011)
-
at MarketWatch.com (Mar 23, 2011)
-
at MarketWatch.com (Mar 22, 2011)
-
at MarketWatch.com (Mar 22, 2011)
PRAN vs. ETF Alternatives
Company Description
Currently, there's no company description for PRAN.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
-
Wednesday, March 6, 12:55 PM
Midday top 10 gainers: OSIR +30%. END +27%. HCI +19%. PCYG +18%. MERU +17%. EGLE +14%. MHH +14%. PRAN +13%. CYTR +13%. VGZ +13%.
Midday top 10 losers: OSH -17%. SCKT -14%. ACUR -12%. OSBC -11%. AEO -11%. AVAV -10%. VSCI -10%. TFM -10%. MFB -10%. MOC -9%. Comment! [On the Move] - Wednesday, March 6, 11:00 AM Midday top 10 gainers: END +30%. OSIR +29%. HCI +19%. REGI +13%. PRAN +12%. CTCM +12%. SHIP +12%. XRM +12%. AACC +12%. MHH +12%. Midday top 10 Losers: OSH -16%. AVAV -14%. ACUR -13%. OSBC -12%. MOC -11%. RWC -10%. TFM -10%. HIMX -10%. AEO -10%. MFB -10%. Comment!
- Wednesday, March 6, 9:35 AM Prana Biotechnology (PRAN) surges 17% after saying that its PBT434 treatment for Parkinson's Disease helped bring "marked improvements in motor function and coordination" in three animal models. PBT434 lowers the accumulation of a key protein called alpha-synuclein, which damages the nerve cells of the substantia nigra part of the part of the brain, where movement is controlled. (PR) (See PBT2 trial) Comment! [Healthcare, On the Move]
-
Wednesday, March 6, 9:10 AM
Premarket gainers: PRAN +13%. PBR +12%. CYTX +9%. PPHM +8%. GEVO +8%. MTG +8%. TSL +8%. HNR +7%. BIG +7%.PBR.A +6%. PAY +5%. WPRT +5%.
Losers: AVAV -25%. TFM -11%. AEO -9%. SOHU -8%. QIHU -5%. NBG -5%. Comment! [On the Move] -
Monday, March 4, 12:55 PM
Midday top 10 gainers: HMG +96%. FOE +33%. HGSH +20%. NQ +18%. MTG +17%. TELOZ +17%. PRAN +15%. OTT +15%. OUTD +15%. YOD +13%.
Midday top 10 losers: DRWI -22%. SCSS -16%. AT -16%. GMXR -15%. TUES -13%. HL -13%. CTC -13%. AUMN -12%. RNIN -12%. RBPAA -12%. Comment! [On the Move] - Monday, March 4, 11:05 AM Prana Biotechnology (PRAN +13.5%) goes on a tear after announcing encouraging new data from its clinical trial of PBT2, a treatment to reduce the damage to brain cells caused by the accumulation of the tau protein - a major protein associated with Alzheimer's Disease - and its ability to prevent subsequent cognitive impairment. Additionally, the company will be presenting an overview and update at Cowen's 33rd Annual Health Care Conference in Boston later this afternoon. Conference Webcast. Comment! [Healthcare, On the Move]
- Thursday, December 20, 2012, 11:51 AM Prana Biotechnology (PRAN +3.2%) moves up after being initiated at Burrill Institutional Research with an Outperform and a price target of $5 a share. Burrill cites the company's progress in developing technology for the treatment of neurodegenerative disorders. Yesterday PRAN announced that it's completed recruitment in its Phase IIa clinical trial using its experimental drug PBT2 for the treatment of patients with Huntington Disease. Comment! [Healthcare, On the Move]
- Thursday, December 13, 2012, 2:37 PM Prana Biotechnology (PRAN +2.6%) gains today after announcing that the Journal of Huntington's Disease has published data showing the benefits of its experimental drug PBT2, for the treatment of Huntington's Disease. The results highlight PBT2's ability to inhibit the development of the symptoms and pathological features of the disease in animal models. The drug is being tested on patients in 20 sites across the USA and Australia, with results expected in Q213. Comment! [Healthcare, On the Move]
- Friday, November 16, 2012, 12:45 PM Midday top 10 gainers: SWSH +30%. PENN +30%. SHF +30%. OMX +20%. PRAN +17%. CCBG +20%. ASCA +15%. SUMR +14%. KWK +14%. OSIS +12%. Midday top 10 Losers: DIAL -76%. SAB -51%. DVAX -47%. SCMR -24%. BORN -20%. VIAS -18%. GAIA -18%. SHLD -17%. SINA -15%. EDS -15%. 2 Comments
-
Thursday, September 27, 2012, 12:45 PM
Midday top 10 gainers: CTC +71.53%. ROYL +31.38%. APPY +18.48%. TPX +16.5%. ULTR +15.6%. WZE +13.09%. STRM +12.7%. IGLD +12.62%. PNX +11.22%. PRAN +11.17%.
Top 10 Losers: PPHM -35.54%. CAFI -12.94%. SYUT -10.64%. CPHD -9.58%. MTE -9.02%. MITK -8.92%. CHYR -8%. CYTX -7.76%. FUL -7.37%. UBNT -7.07%. Comment! [On the Move] -
Tuesday, August 21, 2012, 9:10 AM
Premarket gainers: DEXO +35%. URBN +16%. NDSN +10%. PRAN +7%. PSTI +6%.
Losers: IMUC -15%. BBY -10%. VHC -8%. Comment! [On the Move] - Monday, November 28, 2011, 9:15 AM Prana Biotechnology (PRAN) gains 6% premarket after the firm announces that it secured a key patent for its Parkinson's disease treatment from the USPTO. CEO Geoffrey Kempler says the granted rights will further boost Prana's commercialization plans after a grant from the Michael J. Fox Foundation helped allow the firm to undertake development studies. Comment! [Healthcare, On the Move]
- Monday, September 19, 2011, 10:37 AM Prana Biotechnology (PRAN +16%) soars after The Journal Of Neurochemistry publishes an update on Prana's experimental drug PBT2 for the treatment of Alzheimer's Disease. The study explains how the drug is able to restore cognition in Alzheimer's sufferers by repairing affected Alzheimer's brain sections. Comment! [Healthcare, On the Move]
- Thursday, February 10, 2011, 7:53 AM A series of rate increases, epic cyclones, and biblical flooding are doing wonders for Australian shares, which closed at levels not seen since April. Strength in mining stocks combined with surprisingly good results from the banking sector power the most recent move. ETFs: EWA, KROO. Comment! [Global & FX]
- Monday, January 31, 2011, 4:08 PM Just beginning to dry out from biblical floods, Queensland braces for one of the most powerful cyclones ever on Wednesday/Thursday. Coal exports look to get pushed back again. Stocks and the aussie remain resilient, both near 52 week highs. EWA +1.2%. FXA +0.4%. Some Australian ADRs. 1 Comment [Global & FX]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.